Fig. 1 · Structure

Documents & Downloads

Fesoterodine fumarate

Cat. No. A10386 CAS 286930-03-8

AChR antagonist

Fesoterodine fumarate is a medicine which is used in urinary urgency, reducing the frequency of passing urine and urge urinary incontinence

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
AChR

Fesoterodine fumarate Research Summary

This section summarizes 1 in vivo study of Fesoterodine fumarate from 1 published reference.

Fesoterodine fumarate In Vivo Studies

In female Sprague-Dawley rats with spinal cord transection, continuous subcutaneous fesoterodine fumarate treatment begun at injury lowered selected bladder-pressure endpoints at six weeks. The primary endpoint, intermicturition pressure, was significantly reduced only with uninterrupted 0.12 mg/kg/day treatment; maximum pressure decreased in three of four treated groups. [1]

Treatment did not significantly change baseline pressure, micturition volume, bladder capacity or residual volume versus untreated injured controls. Metabolic-cage voiding measures also showed no significant treatment differences. These short-term rat findings do not establish long-term prevention or the proposed receptor-remodeling mechanism. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Early continuous fesoterodine fumarate in a spinal cord transected rat model

Animal study · 33 female Sprague-Dawley rats randomly allocated to six groups: normal controls n=3; untreated injured controls and four injured treatment groups n=6 each. Awake cystometry at six weeks. [1]

One experiment includes both doses, washout groups, cystometry and longitudinal metabolic-cage endpoints. Selected pressure outcomes improved; primary IMP significance was confined to uninterrupted low-dose treatment. Volume endpoints and metabolic-cage measures did not significantly differ from injured controls. No mortality was reported.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Intermicturition pressure at six weeks; groups 2, 3, 4, 5 and 6 respectivelymean; median; range (cmH2O) 22.9; 18.6; (15.1–48.5) | 13.4; 11.3; (4.9–26.5) | 12.7; 13.0; (5.4–18.3) | 15.2; 15.2; (12.2–17.9) | 18.1; 19.8; (8.4–22.5)[1]
Maximum pressure versus untreated injured controlsreported significance Groups 3 and 4: p<0.01; group 5: p<0.05; group 6: no significant difference[1]
Threshold pressure versus untreated injured controlsreported significance Groups 3 and 4: p<0.05; groups 5 and 6: no significant difference[1]
Baseline pressure, micturition volume, bladder capacity, residual volume; metabolic-cage micturition volume and frequencyreported comparison No significant differences between treated injured rats and untreated injured controls[1]

Conditions shared by the study groups

Route
Subcutaneous osmotic pump
Frequency
Continuous delivery
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Group 3: FF 0.18
0.18 mg/kg/day
Group 2: untreated spinal cord transected rats, n=6; group 1: normal rats, n=3, establishes injury-associated changesIMP not significantly reduced; Pmax p<0.01 and Pthres p<0.05 versus group 2. Baseline pressure and cystometric volume endpoints were not significantly different from group 2.[1]
Group 4: FF 0.12
0.12 mg/kg/day
Group 2: untreated spinal cord transected rats, n=6; group 1: normal rats, n=3, establishes injury-associated changesIMP p<0.05, Pmax p<0.01 and Pthres p<0.05 versus group 2. Baseline pressure and cystometric volume endpoints were not significantly different from group 2.[1]
Group 5: FF 0.18 plus 72-h washout
0.18 mg/kg/day
Group 2: untreated spinal cord transected rats, n=6; group 1: normal rats, n=3, establishes injury-associated changesPmax p<0.05; IMP and Pthres not significantly reduced versus group 2. Baseline pressure and cystometric volume endpoints were not significantly different from group 2.[1]
Group 6: FF 0.12 plus 72-h washout
0.12 mg/kg/day
Group 2: untreated spinal cord transected rats, n=6; group 1: normal rats, n=3, establishes injury-associated changesIMP, Pmax and Pthres not significantly reduced versus group 2. Baseline pressure and cystometric volume endpoints were not significantly different from group 2.[1]
Group 3: FF 0.18
Model: Female Sprague-Dawley rats, 350–400 g, spinal cord transection at T10; n=6 per group
Treatment course: Started at transection; continuous through six-week cystometry
Reported limits: Vehicle composition, analytical purity, lot and separate stereochemical verification are not reported in the acquired article. Injured controls were untreated; no vehicle-pump control is described.
Group 4: FF 0.12
Model: Female Sprague-Dawley rats, 350–400 g, spinal cord transection at T10; n=6 per group
Treatment course: Started at transection; continuous through six-week cystometry
Reported limits: Vehicle composition, analytical purity, lot and separate stereochemical verification are not reported in the acquired article. Injured controls were untreated; no vehicle-pump control is described.
Group 5: FF 0.18 plus 72-h washout
Model: Female Sprague-Dawley rats, 350–400 g, spinal cord transection at T10; n=6 per group
Treatment course: Started at transection; pump removed 72 h before six-week cystometry
Reported limits: Vehicle composition, analytical purity, lot and separate stereochemical verification are not reported in the acquired article. Injured controls were untreated; no vehicle-pump control is described.
Group 6: FF 0.12 plus 72-h washout
Model: Female Sprague-Dawley rats, 350–400 g, spinal cord transection at T10; n=6 per group
Treatment course: Started at transection; pump removed 72 h before six-week cystometry
Reported limits: Vehicle composition, analytical purity, lot and separate stereochemical verification are not reported in the acquired article. Injured controls were untreated; no vehicle-pump control is described.
Methods and source locations

Compound reported in the paper: Fesoterodine fumarate; Compound label in the paper: FF

Reported fumarate treatment in this rat model only; no conversion to free-base doses, supplier validation, human efficacy, durable prevention or molecular remodeling claim.

Materials and Methods: Study design, Experimental animals, Osmotic pump implantation/removal, Cystometry, Statistical analysis; Results; Table 2; Figures 3–5

Intermicturition pressure at six weeks; groups 2, 3, 4, 5 and 6 respectively: Awake cystometry; n=6 rats per injured group. Only group 4 differs significantly from group 2 (p<0.05), post-hoc Dunn’s test for Kruskal-Wallis analysis. Means, medians and ranges are distinct, not ± errors. — Table 2, IMP row and footnote; Figure 3 axis; Methods: Cystometry, Study design, Statistical analysis

Maximum pressure versus untreated injured controls: Post-hoc Dunn’s test for Kruskal-Wallis analysis; n=6 rats per injured group. — Table 2, Pmax row and footnote; Results: Maximum pressure; Figure 4

Threshold pressure versus untreated injured controls: Post-hoc Dunn’s test for Kruskal-Wallis analysis; n=6 rats per injured group. — Table 2, Pthres row and footnote; Results: Threshold pressure; Figure 5

Baseline pressure, micturition volume, bladder capacity, residual volume; metabolic-cage micturition volume and frequency: Cystometry at six weeks; metabolic-cage recordings for 6 h once weekly during weeks 3–5. No claim of equivalence. — Table 2, Pbase/MV/BC/RV rows; Results: Other cystometric parameters; Metabolic cage parameters; Methods: Metabolic cage recording

Group 3: FF 0.18 · Methods: Study design; Experimental animals; Osmotic pump implantation/removal; Results; Table 2 and footnote

Group 4: FF 0.12 · Methods: Study design; Experimental animals; Osmotic pump implantation/removal; Results; Table 2 and footnote

Group 5: FF 0.18 plus 72-h washout · Methods: Study design; Experimental animals; Osmotic pump implantation/removal; Results; Table 2 and footnote

Group 6: FF 0.12 plus 72-h washout · Methods: Study design; Experimental animals; Osmotic pump implantation/removal; Results; Table 2 and footnote

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 286930-03-8
Applications AChR antagonist
Formula C26H37NO3.C4H4O4
Molecular Weight 527.7
Synonyms Toviaz
SMILES
CC(C)C(=O)OC1=C(C=C(C=C1)CO)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2.C(=C/C(=O)O)\C(=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 99 mg/mL (187.61 mM)
Water 99 mg/mL (187.61 mM)
Ethanol 99 mg/mL (187.61 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Fesoterodine fumarate Research References

  1. [1] Xavier Biardeau, Mikolaj Przydacz, Shachar Aharony, et al. Early Fesoterodine Fumarate Administration Prevents Neurogenic Detrusor Overactivity in a Spinal Cord Transected Rat Model PLoS ONE (2017). PMID: 28060912 DOI: 10.1371/journal.pone.0169694 Source material

Added to your cart

View Cart Checkout
Loading...